In one paragraphArticle in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Brooke DirvinColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0002-3948-1548 Heeju NohDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0002-9299-4852 Lorenzo TomassoniDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0002-7720-9166 Danting CaoColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0009-0003-7469-4033 Yizhuo ZhouColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0003-1903-0798 Xiangyi KeColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0009-0008-4923-1922 Jun QianColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0009-0009-4473-3912 Sonia JangraDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-5671-1632 Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-3156-3132 Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-6551-1827 Charles KaranHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0003-4012-8677 Andrea CalifanoHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0003-4742-3679 Wellington V CardosoColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0002-8868-9716 Funding
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2MPredicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5MMechanisms Controlling Expansion and Lineage Specification of Airway Progenitors in Development and DiseaseR35HL135834 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CARDOSO, WELLINGTON V. · 2017 to 2023
$6.7MElucidating and Targeting tumor dependencies and drug resistance determinants at the single cell levelU01CA272610 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2022 to 2026
$4.8MRegulation of Progenitor Cell Plasticity in Lung Development and Disease-RepairR35HL166661 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Wellington V. Cardoso · 2023 to 2026
$4.4MCombined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacyR01AI160706 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2022 to 2025
$2.9MHigh Performance Computing Cluster for Biomedical ResearchS10OD032433 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2023 to 2023
$2.0MHigh-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0MExperimental and natural SARS-CoV-2 infection of the human pancreasR01DK130425 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOMANN, DIRK, SCHOTSAERT, MICHAEL · 2021 to 2023
$1.3MStorage System for High Performance ComputingS10OD021764 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2016 to 2016
$600kNCI NIH HHS R35 CA197745NCI NIH HHS U01 CA272610NHLBI NIH HHS R35 HL135834NHLBI NIH HHS R35 HL166661NIAID NIH HHS R01 AI160706NIAID NIH HHS U19 AI135972NIDDK NIH HHS R01 DK130425NIH HHS S10 OD012351NIH HHS S10 OD021764NIH HHS S10 OD032433
6 · The paper itselfAbstract
The impact of SARS-CoV-2 in the lung has been extensively studied, yet the molecular regulators of host-cell programs hijacked by the virus in distinct human airway epithelial cell populations remain poorly understood. Some of the reasons include overreliance on transcriptomic profiling and use of nonprimary cell systems. Here we report a network-based analysis of single-cell transcriptomic profiles able to identify master regulator (MR) proteins controlling SARS-CoV-2-mediated reprogramming in pathophysiologically relevant human ciliated, secretory, and basal cells. This underscored chromatin remodeling, endosomal sorting, ubiquitin pathways, as well as proviral factors identified by CRISPR assays as components of the viral-host response in these cells. Large-scale drug perturbation screens revealed 11 candidate drugs able to invert the entire MR signature activated by SARS-CoV-2. Leveraging MR analysis and perturbational profiles of human primary cells represents an innovative approach to investigate pathogen-host interactions in multiple airway conditions for drug prioritization.
Indexed as
COVID-19Host-Pathogen InteractionsRespiratory MucosaSARS-CoV-2Antiviral AgentsEpithelial CellsGene Expression ProfilingHumansSingle-Cell AnalysisTranscriptomeAntiviral Agents
Identifiers
PMID40378209
PMCPMC12083520
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390